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Interleukin-1 Blockade Inhibits the Acute Inﬂammatory Response in
Patients With ST-Segment–Elevation Myocardial Infarction
Antonio Abbate, MD, PhD; Cory R. Trankle, MD; Leo F. Buckley, PharmD; Michael J. Lipinski, MD, PhD; Darryn Appleton, MD;
Dinesh Kadariya, MD; Justin M. Canada, PhD; Salvatore Carbone, PhD; Charlotte S. Roberts, NP; Nayef Abouzaki, MD;
Ryan Melchior, DO; Sanah Christopher, MD; Jeremy Turlington, MD; George Mueller, DO; James Garnett, MD; Christopher Thomas, MD;
Roshanak Markley, MD; George F. Wohlford, PharmD; Laura Puckett, RN; Horacio Medina de Chazal, MD; Juan G. Chiabrando, MD;
Edoardo Bressi, MD; Marco Giuseppe Del Buono, MD; Aaron Schatz, MD; Chau Vo, MD; Dave L. Dixon, PharmD;
Giuseppe G. Biondi-Zoccai, MD, MStat; Michael C. Kontos, MD; Benjamin W. Van Tassell, PharmD

Background-—ST-segment–elevation myocardial infarction is associated with an intense acute inﬂammatory response and risk of
heart failure. We tested whether interleukin-1 blockade with anakinra signiﬁcantly reduced the area under the curve for hsCRP
(high sensitivity C-reactive protein) levels during the ﬁrst 14 days in patients with ST-segment–elevation myocardial infarction
(VCUART3 [Virginia Commonwealth University Anakinra Remodeling Trial 3]).
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Methods and Results-—We conducted a randomized, placebo-controlled, double-blind, clinical trial in 99 patients with STsegment–elevation myocardial infarction in which patients were assigned to 2 weeks treatment with anakinra once daily (N=33),
anakinra twice daily (N=31), or placebo (N=35). hsCRP area under the curve was signiﬁcantly lower in patients receiving anakinra
versus placebo (median, 67 [interquartile range, 39–120] versus 214 [interquartile range, 131–394] mgday/L; P<0.001), without
signiﬁcant differences between the anakinra arms. No signiﬁcant differences were found between anakinra and placebo groups in
the interval changes in left ventricular end-systolic volume (median, 1.4 [interquartile range, 9.8 to 9.8] versus 3.9 [interquartile
range, 15.4 to 1.4] mL; P=0.21) or left ventricular ejection fraction (median, 3.9% [interquartile range, 1.6% to 10.2%] versus
2.7% [interquartile range, 1.8% to 9.3%]; P=0.61) at 12 months. The incidence of death or new-onset heart failure or of death and
hospitalization for heart failure was signiﬁcantly lower with anakinra versus placebo (9.4% versus 25.7% [P=0.046] and 0% versus
11.4% [P=0.011], respectively), without difference between the anakinra arms. The incidence of serious infection was not different
between anakinra and placebo groups (14% versus 14%; P=0.98). Injection site reactions occurred more frequently in patients
receiving anakinra (22%) versus placebo (3%; P=0.016).
Conclusions-—In patients presenting with ST-segment–elevation myocardial infarction, interleukin-1 blockade with anakinra
signiﬁcantly reduces the systemic inﬂammatory response compared with placebo.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT01950299. ( J Am Heart Assoc. 2020;9:
e014941. DOI: 10.1161/JAHA.119.014941.)
Key Words: acute myocardial infarction • interleukin-1 • heart failure • ST-segment–elevation myocardial infarction

S

T-segment–elevation myocardial infarction (STEMI)
remains a major cause of morbidity and mortality worldwide. Despite considerable advances in STEMI treatment, up to
30% of survivors develop heart failure (HF) and 10% are

hospitalized for HF within 1 year.1–4 This observation suggests
that the current treatment paradigm misses ≥1 key pathophysiologic mechanisms. A close interplay exists between inﬂammation, healing after STEMI, and progression to HF. Acute
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What Is New?
• Interleukin-1 blockade signiﬁcantly reduced the acute
inﬂammatory response in patients with ST-segment–elevation myocardial infarction.
• This reduction in inﬂammatory signaling was accompanied
by signiﬁcant reductions in new-onset heart failure and
hospitalization for heart failure.

What Are the Clinical Implications?
• Targeted anti-inﬂammatory treatment with interleukin-1
blockers may be a novel approach to reduce the risk of heart
failure after ST-segment–elevation myocardial infarction.
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myocardial ischemia and infarction initiate an intense inﬂammatory response.5 The degree of the inﬂammatory response
in STEMI is a strong predictor of adverse cardiac remodeling
independent of infarct size.5,6 Likewise, in patients with
STEMI, the intensity of the inﬂammatory response, reﬂected
in levels of circulating biomarkers, predicts adverse cardiac
remodeling, HF, and death.7 Modulation of the inﬂammatory
response, therefore, represents a potential target for intervention. Although many previous attempts to target inﬂammation have failed,5 interleukin-1 blockade is a novel and
substantially different approach to modulating the inﬂammatory response.8 Preclinical studies have shown that anakinra,
a recombinant interleukin-1 receptor antagonist, improves
myocardial healing, preventing additional cardiomyocyte loss,
adverse remodeling, and HF in experimental myocardial
infarction.9 Two pilot clinical trials showed preliminary safety
and feasibility of treatment with recombinant interleukin-1
receptor antagonist, anakinra, in STEMI (VCUART [Virginia
Commonwealth University Anakinra Remodeling Trial]10 and
VCUART211,12). Moreover, the CANTOS (Canakinumab
Atherothrombosis Outcome Trial) showed prevention of
recurrent ischemic events and of hospitalizations for HF in
patients with prior myocardial infarction treated with
canakinumab, an interleukin-1b blocking antibody.13,14
The objective of this study was to determine whether
anakinra, 100 mg once daily (standard dose) or twice daily
(high dose), signiﬁcantly reduced systemic inﬂammation
(versus placebo) in patients with STEMI (primary end point)
and whether this treatment resulted in better preservation of
left ventricular (LV) systolic function and/or reduced incidence of HF events (secondary end points).

Trial Design
The VCUART3 was a phase 2, multicenter, double-blinded,
randomized, placebo-controlled clinical trial comparing anakinra, 100 mg once daily (standard dose), alternated with
placebo, once daily, every 12 hours, 100 mg twice daily (high
dose), or placebo twice daily (in 1:1:1 ratio). The study design
has been previously published.15 The trial protocol (available
online) and all subsequent amendments received approval by
the local Institutional Review Boards.

Screening and Enrollment
We screened consecutive patients, aged ≥21 years, who
presented to the hospital with acute STEMI and underwent
urgent coronary angiography within 12 hours of symptom
onset at the Virginia Commonwealth University (VCU) Health
(Richmond, VA), Virginia Cardiovascular Specialists (Richmond, VA), or Medstar Washington Hospital Center (Washington, DC). All subjects provided written informed consent in
accordance with the local Institutional Review Board. Patients
were excluded from the study if they had contraindications to
treatment with anakinra, chronic inﬂammatory or infectious
disease, or preexisting structural or functional severe cardiac
abnormalities (Table S1 includes a complete list of inclusion
and exclusion criteria).

Randomization and Masking
Anakinra and identical matching placebo syringes were handled
by the investigational pharmacy at the coordinating center
(VCU). A randomization log was prepared and maintained at the
investigational pharmacy at VCU. The syringes were sequentially numbered from 1 to 28 to maintain allocation concealment, and patients were instructed to inject the syringes
sequentially so to alternate odd-numbered syringes in the
morning and even-numbered syringes in the evening. The
investigational drug was prepared at VCU and shipped to the
other centers in blocks of 5.

Investigational Treatment
Patients were randomly assigned to receive anakinra, 100 mg
once daily (standard dose), alternating with placebo, once daily
every 12 hours for 14 days; anakinra, 100 mg twice daily, every
12 hours (high dose) for 14 days; or placebo twice daily every
12 hours for 14 days, with the ﬁrst dose administered within
12 hours of coronary angiography. Patients in the study received
guideline-based medical treatments, as indicated. Compliance
was deﬁned as >80% of prescribed doses of investigational drug.

Methods

Laboratory Analysis and Biomarkers

The study design and results of the study are posted online on
https://clinicaltrials.gov/ct2/show/NCT01950299.

Blood samples were used for a complete blood cell count with
differential, comprehensive metabolic proﬁle, and plasma
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involved in the conduct of the study procedures, adjudicated
all events (Protocol). Prespeciﬁed HF end points included the
combined incidence of death and new onset of HF (deﬁned as
hospitalization for HF or need for a new initiation of a loop
diuretic in the appropriate clinical setting; D+HF) and the
composite of all-cause death and hospitalization for HF
(D+HHF), as speciﬁed in a consensus document on the
deﬁnition of HF end points in STEMI trials.19 Additional
adjudicated events included recurrent myocardial infarction,
urgent revascularization, and severe infections.

Safety Assessment
All patients underwent a complete physical examination and
clinical evaluation at each visit. A Data and Safety Monitoring
Board, composed of cardiologists, a general internal medicine
specialist, and an infectious disease specialist, reviewed study
progress and safety data every 6 months (Protocol).

Sample Size and Statistical Analysis
Doppler Echocardiography

Downloaded from http://ahajournals.org by on June 5, 2020

Subjects underwent a transthoracic Doppler echocardiogram
within 24 hours of enrollment and at 1-year follow-up, as part
of their clinical care and as previously described.10,11,15
Paired measurements of LV end-diastolic and end-systolic
volumes and calculation of LV ejection fraction occurred offline at the end of the study by a core laboratory with 2
separate operators blinded to group allocations. The average
of the 2 measurements was used for measures differing
≤10%, whereas those with >10% difference were rereviewed
by a third operator and discussed to achieve consensus.

Primary and Secondary End Points
The primary end point was the AUC for hsCRP, measured at
baseline, 72 hours, and day 14. hsCRP is an established
prognostic marker in STEMI that reﬂects systemic interleukin-1
activity.18 Measuring AUC for hsCRP allowed for integration of
measurements across multiple time points to more accurately
quantify the acute inﬂammatory response. The primary end
point analysis compared both anakinra groups with placebo (P
for signiﬁcance set at <0.05), followed by a comparison of the
anakinra, 100 mg twice daily, group with the placebo group and
the anakinra, 100 mg daily, group with the placebo group,
separately (P for signiﬁcance set at <0.025).
Secondary end points included interval changes in LV endsystolic volume and ejection fraction between baseline and
12 months and the incidence of HF. An independent
committee composed of physicians specializing in internal
medicine, cardiology, or emergency medicine, who were
blinded to treatment allocation and to hsCRP data and not
DOI: 10.1161/JAHA.119.014941

The sample size for this study was calculated on the basis of
the primary outcome of comparing hsCRP-AUC with anakinra
(both groups) versus placebo, to be followed (if signiﬁcant) by
an analysis of each anakinra group (standard and high dose)
versus placebo. Given an expected hsCRP-AUC of
350250 mgday/L for placebo-treated patients with STEMI
and 175150 mgday/L for anakinra (standard dose), 33
patients per group would provide >99% power (a=0.05) to
detect a difference versus placebo and 85% power (2-tailed a
0.025 considering multiple testing) to detect a further 50%
reduction in the anakinra (high dose) (estimated AUC for
hsCRP of 8875 mgday/L) versus anakinra (standard dose).
A 20% loss to follow-up or withdrawal was expected to retain
>80% power for all analyses. No missing data imputation was
used.
For statistical analysis, all values are reported as the
median and interquartile range for potential deviation from
gaussian distribution. All analyses were performed on an
intention-to-treat basis without imputation for missing data.
The differences between treatment groups were computed
using the Wilcoxon or Kruskal-Wallis rank-sum test for 2
groups (anakinra [both groups] versus placebo) or 3 groups,
respectively, for continuous variables. The differences in
interval changes between the treatments were compared
using random-effect ANOVA for repeated measures to analyze
the effects of time and group allocation. Unadjusted P values
are reported throughout, with statistical signiﬁcance set at
the 2-tailed P of 0.05 for the comparison of both anakinra
groups versus placebo and of 0.025 for analysis of each dose
group versus placebo. Kaplan-Meier curves for survival free of
HF events between anakinra (combined) and placebo were
Journal of the American Heart Association
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levels of hsCRP (high sensitivity C-reactive protein) (True
Health Diagnostics, Richmond, VA). All study personnel were
kept blinded to hsCRP levels.
Creatine kinase myocardial band (CK-MB) levels were
determined by direct chemiluminescent technology every
6 hours starting immediately after percutaneous coronary
intervention until peak, according to the local clinical
standard. We estimated infarct size on the basis of the
time-concentration area under the curve (AUC) of CK-MB.16,17
CK-MB peak value was deﬁned as the maximal CK-MB level
measured during hospitalization. For patients with <6
recorded CK-MB measurements, we estimated AUC for CKMB by a validated log-normal model incorporating the
admission CK-MB level, the CK-MB peak level, and the time
to CK-MB peak to reconstruct the typical time course of CKMB curve.16,17 The time to CK-MB peak, as a measure of
duration of myocardial injury, was considered as the time
between the initial onset of symptoms (chest pain per patient
report) and the CK-MB peak level.

VCUART3 Randomized Clinical Trial

Abbate et al

Results
Screening and Randomization
Between July 2014 and December 2017, 311 patients were
screened and 99 were randomized to anakinra once daily
(standard dose; N=33 [33%]), anakinra twice daily (high dose;
N=31 [31%]), or placebo (N=35 [35%]). The main reasons for
exclusion were patient preference (N=53), inability to provide
consent (N=39), active or chronic infection (N=27), or active or
recent cancer (N=23; Figure 1). All 99 patients (100%) received
at least 1 dose of investigational drug, and 77 (78%) had
complete biomarker data available for baseline, in-hospital, and
2-week follow-up, allowing for the assessment of the primary
end point of hsCRP-AUC (Figure 1). Clinical follow-up was
available for all 99 subjects (100%), ranging from 3 to 365 days,
311 patients were screened between
July 2014 and December 2017

Downloaded from http://ahajournals.org by on June 5, 2020

212 patients were excluded prior
to randomization

Patient preference (N=53);
unable to consent (N=39);
Infection (N=27); Cancer
(N=23); failed PCI (N=13);
stage IV-V CKD (N=12);
Late presentation (N=11);
stage C-D systolic HF (N=5);
other (N=29)

Anakinra
once daily
(N=33)

Missing
samples
(N=11)
Data available
for hsCRP AUC at
14 days
(N=77)

Treatment with
investigational drug

99

Anakinra
once daily
(N=22)

Anakinra
twice daily
(N=31)

Placebo
(N=35)

Missing
samples
(N=7

Missing
samples
(N=4)

Anakinra
twice daily
(N=27)

Placebo
(N=28)

Follow up at 3,
6 and 12
months

Event
Adjudication
(N=99)

Anakinra
once daily
(N=33

Anakinra
twice daily
(N=31)

Placebo
(N=35)

Figure 1. Enrollment, randomization, and follow-up. AUC indicates area under the curve; CKD, chronic kidney disease; hsCRP,
high-sensitivity C-reactive protein; HF, heart failure; PCI, percutaneous coronary intervention.
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with a median follow-up duration of 365 (interquartile range,
287–365) days, with 71 (72%) with 365 days of follow-up and
87 (88%) with >180 days of follow-up.

Characteristics of the Patients
Table 1 summarizes the clinical and demographic characteristics of the patients. Guideline-directed therapies at time of
enrollment and at the end of the study are shown in Table S2.
There were no clinically meaningful differences between the
groups. The estimated infarct size using the AUC for CK-MB
was not statistically different comparing the different groups
(Table 1). The number of patients who completed all 14 days
of treatment was not different between the groups (24 [73%],
27 [87%], and 24 [69%] for anakinra once daily, anakinra twice
daily, and placebo, respectively; P=0.19).

AUC of hsCRP During the First 14 Days After STEMI
The hsCRP-AUC values during the ﬁrst 14 days were available in
22 (67%), 27 (87%), and 28 (80%) of the anakinra once daily,
anakinra twice daily, and placebo groups, respectively, without
signiﬁcant difference in the incidence of missing data between
groups (P=0.15 comparing the 3 groups, and P=0.80 comparing
pooled anakinra group versus placebo). When compared with
placebo, the hsCRP-AUC value for the ﬁrst 14 days was
signiﬁcantly lower in the pooled anakinra group (both doses
combined) versus the placebo group (median, 67 [interquartile
range, 39–120] versus 214 [interquartile range, 131–394]
mgday/L; P<0.001; Figure 2, Figure S1). Each anakinra arm
analyzed individually versus placebo signiﬁcantly reduced
hsCRP-AUC (P<0.001) without signiﬁcant differences between
the 2 anakinra arms (median, 60 [interquartile range, 24–139]
versus 86 [interquartile range, 43–123] mgday/L, for once and
twice daily anakinra, respectively; P=0.41; Figure 2, Figure S1).
The most common reason for missing data was related to lack
of blood sample at 72 hours or discharge.

Effects on LV Dimensions and Systolic Function
Paired echocardiography studies were available in 63 of 99
patients (64%) at a median of 362 days (interquartile range,
336–375 days) after the baseline study: 24 of 35 (69%)
placebo patients and 39 of 64 (60%) anakinra patients (both
doses combined). Table S3 shows the characteristics of the
subjects with paired echocardiographic data. Baseline LV enddiastolic volume, LV end-systolic volume, stroke volume, and
LV ejection fraction were not signiﬁcantly different comparing
placebo and anakinra (all P>0.05). No signiﬁcant differences
were found between anakinra and placebo groups in the
interval changes in LV end-systolic volume (median, 1.4
[interquartile range, 9.8 to 9.8] versus 3.9 [interquartile
Journal of the American Heart Association
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constructed and compared using the log-rank (Mantel-Cox)
test. The v2 or Fisher exact tests were used for discrete
variables. All analyses were completed using the Statistical
Package for Social Sciences, version 24.0 (SPSS, Chicago, IL).
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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Table 1. Characteristics of the Patients at Baseline
Characteristics

Anakinra, Once Daily (N=33)

Anakinra, Twice Daily (N=31)

Placebo (N=35)

Age, y

53 (49–62)

55 (45–61)

56 (51–65)

Female sex

9 (27)

5 (16)

5 (14)

White/black/Hispanic/other

19:12:2:3

17:9:2:3

21:6:3:5

Symptom onset to PCI time, min

210 (128–280)

145 (88–435)

180 (130–347)

Symptom onset to investigational
drug administration, min

509 (405–644)

450 (300–745)

529 (403–716)

Fibrinolytic use before PCI

1 (3)

4 (13)

3 (9)

LAD occlusion

13 (39)

13 (42)

11 (30)

RCA occlusion

12 (36)

13 (42)

18 (50)

LCX occlusion

7 (21)

5 (16)

6 (17)

Culprit vessel

1 (3)

0

1 (3)

TIMI flow grade 0/1 pre-PCI

SVG occlusion

30 (91)

27 (87)

25 (71)

TIMI flow grade 3 post-PCI

33 (100)

31 (100)

35 (100)

PCI type

Downloaded from http://ahajournals.org by on June 5, 2020

Primary PCI

32 (97)

27 (87)

32 (91)

PCI after fibrinolysis

1 (3)

4 (13)

3 (9)

Coronary stent implantation

28 (85)

30 (97)

35 (100)

Use of drug-eluting stent

19 (57)

25 (81)

30 (86)

Use of thrombectomy

6 (18)

4 (13)

6 (17)

Use of a P2Y12 inhibitor

33 (100)

31 (100)

35 (100)

Clopidogrel

5 (15)

4 (13)

7 (20)

Prasugrel

10 (30)

12 (39)

12 (34)

Ticagrelor

18 (55)

15 (48)

16 (46)

5 (2–21)

11 (3–58)

7 (2–28)

Initial CK-MB level, ng/mL
Peak CK-MB level, ng/mL

100 (30–205)

134 (80–282)

93 (36–252)

CK-MB AUC at 14 d, ng/mL*d

2054 (957–3370)

3051 (1493–4694)

2351 (765–4668)

Time to peak, min

493 (321–740)

450 (343–603)

446 (281–623)

Previous diagnosis of CAD

6 (18)

8 (26)

7 (20)

Diabetes mellitus

6 (18)

9 (29)

15 (43)

Systemic arterial hypertension

13 (39)

20 (64)

23 (66)

LVEF (initial assessment), %

51 (43–58)

48 (43–58)

53 (42–57)

Data are presented as number (percentage) or median (interquartile range) for categorical or continuous variables, respectively. AUC indicates area under the curve; CAD, coronary artery
disease; CK-MB, creatine kinase myocardial band; LAD, left anterior descending artery; LCX, left circumﬂex artery; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary
intervention; RCA, right coronary artery; SVG, saphenous venous graft; TIMI, Thrombolysis in Myocardial Infarction.

range, 15.4 to 1.4] mL; P=0.21) or LV ejection fraction
(median, 3.9% [interquartile range, 1.6% to 10.2%] versus
2.7% [interquartile range, 1.8% to 9.3%]; P=0.61).

Effects on Clinical Events
There was 1 death (3%) in the placebo group and none in the
anakinra group (Table 2). Compared with placebo, treatment
with anakinra was associated with a signiﬁcant reduction
DOI: 10.1161/JAHA.119.014941

versus placebo in the incidence of the composite end point of
all-cause death and new-onset or worsening HF (6/64 [9.4%]
versus 9/35 [25.7%]; log-rank v2=3.995; P=0.046), as well as
a reduction in the composite end point of all-cause death and
hospitalization for HF (0/64 [0%] versus 4/35 [11.4%]; logrank v2=6.516; P=0.014), without any signiﬁcant difference
between the 2 anakinra arms (Table 2, Figure 3, Figure S2).
There was no difference in the composite end point of
death, recurrent myocardial infarction, or urgent
Journal of the American Heart Association
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Discussion
Figure 2. Effects of anakinra on hsCRP (high-sensitivity C-reactive
protein). Anakinra, once daily or twice daily, signiﬁcantly reduced
the area under the curve for hsCRP at 14 days (shaded areas)
(P<0.001 for each anakinra group vs placebo, and P<0.001 for
anakinra groups combined vs placebo). We found no signiﬁcant
difference between the once-daily and twice-daily anakinra regimens (P=0.41). Data are presented as median and interquartile
range.

Downloaded from http://ahajournals.org by on June 5, 2020

revascularization: 6 in the anakinra group (9%) and 5 (14%) in
placebo group (P>0.05; Table 2, Figure 3).
Treatment with anakinra was well tolerated, with no serious
unanticipated adverse events. Nine patients in the anakinra
group (14%) and 5 in the placebo group (14%; P=0.98)
experienced a serious infection requiring prescription of an
antimicrobial drug, all considered to be unrelated to the
investigational treatment (Table 2). Injection site reactions
were signiﬁcantly more common in the anakinra group than in
placebo (16/64 [22%] versus 1/35 [3%]; P=0.016), leading to
early interruption of treatment in 6 anakinra-treated patients
(9%) and 1 placebo-treated patient (3%; P=0.419). There was no
signiﬁcant difference in any of the other end points comparing
anakinra, once daily, with anakinra, twice daily (Table 2).

Sensitivity Per-Protocol Analysis
We performed a per-protocol analysis in which subjects were
analyzed on the basis of treatment received rather than
treatment assigned when we found, discovered during the
study closure procedures for one of secondary sites, that 3
patients received a treatment different than originally
assigned. When we analyzed per protocol comparing anakinra
combined (N=65) versus placebo (N=34), the signiﬁcance in
hsCRP-AUC and HF events (D+HF and D+HHF) was conﬁrmed
(P<0.001, P=0.032, and P=0.007, respectively).

Additional Exploratory Analysis on LV
Performance
During the recording of the Doppler echocardiogram, using
noninvasive 2-dimensional–derived LV volumes, measures of
DOI: 10.1161/JAHA.119.014941

The results of this phase 2 clinical trial support the safety of
standard and high-dose anakinra in patients with STEMI and
demonstrate that either dose of anakinra blunts the acute
inﬂammatory response, as measured by the hsCRP-AUC at
14 days. The degree of hsCRP plasma elevation predicts inhospital mortality and long-term incidence of HF in patients
with STEMI.3,5–7,17,18 The strong reduction in hsCRP levels
with anakinra, at both standard and high dose, conﬁrms prior
ﬁndings of enhanced interleukin-1 activity in patients with
STEMI.8–12 The lack of differences between standard and
high-dose anakinra suggests that the standard daily dose is
sufﬁcient to block the interleukin-1 receptor and modulate the
inﬂammatory response in STEMI.
Consistent with what was seen in preclinical experimental
models,8,9 the beneﬁts of anakinra appear to be independent of
difference of infarct size, supporting an effect of interleukin-1
blockade on the healing of the myocardium after acute
myocardial infarction. We explored the effects of anakinra on
interval changes in LV dimensions and function at 12 months.
Adverse remodeling is considered to be a primary substrate for
HF complicating STEMI3,4; however, data from this study show
minimal changes in LV volumes and systolic function among
placebo- and anakinra-treated patients. These data suggest
that current strategies of prompt reperfusion and early
neurohormonal blockade are sufﬁcient to suppress adverse
cardiac remodeling after STEMI. Despite these advances in
treatment and the reduction in adverse remodeling, the
incidence of subsequent new or worsening HF after STEMI
remains unacceptably high, affecting up to 30% of patients at 1
year,1,2 which may imply an additional pathway for progression
to HF independent of traditional measures of cardiac remodeling. In an exploratory analysis, we show that patients treated
with anakinra tend to improve LV performance (stroke volume
and stroke work21) beyond what is seen in placebo. The role of
interleukin-1 in inhibiting cardiac contractility is well known
from experimental studies in cells and animals.8 Previous
studies have shown improvement in systolic function with
interleukin-1 blockade in patients with systolic HF and associated improvement in cardiorespiratory ﬁtness.20,22–25
Journal of the American Heart Association
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arterial blood pressure, and Doppler-derived estimates of LV
pressure, we calculated also LV stroke volume and stroke work
(stroke work=stroke volume*[mean arterial pressure – left
ventricular end diastolic pressure]),20 surrogates for LV performance.21 Compared with placebo, anakinra led to a signiﬁcant
improvement in stroke volume (P=0.001 versus baseline and
P=0.027 for time9group interaction versus placebo) and stroke
work (P=0.001 versus baseline and P=0.004 for time9group
interaction versus placebo) (Figure S3).
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Table 2. Safety and Efﬁcacy Outcomes

Outcome

Anakinra, Once
Daily (N=33)

Anakinra, Twice
Daily (N=31)

Placebo (N=35)

P Value Between
Groups

Anakinra
Combined (N=64)

P Value Versus
Placebo

Death

0

0

1 (3)

0.40

0

0.17

Death or hospitalization for heart failure

0

0

4 (11)

0.022*

0

0.014*

Death or new-onset or worsening heart failure
(including outpatient and hospitalization)

3 (9)

3 (10)

9 (26)

0.09

6 (9)

0.041*

Death, recurrent acute myocardial infarction,
or urgent revascularization

5 (15)

1 (3)

5 (14)

0.24

6 (9)

0.51

Death or stroke

1 (3)

1 (3)

1 (3)

0.99

2 (3)

0.95

Sepsis or serious infection

3 (9)

6 (19)

5 (14)

0.24

9 (14)

0.98

Death or serious infections

3 (9)

6 (19)

5 (14)

0.24

9 (14)

0.98

Injection site reactions

6 (18)

8 (26)

1 (3)

0.029*

14 (22)

0.016*

Injection site reaction leading to discontinuation

3 (9)

2 (6)

1 (3)

0.56

6 (9)

0.42

Data are presented as number (percentage). P values reported for v2 or Fisher exact test.
*P<0.05.
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Anakinra was also studied in the MRC-ILA Heart clinical
trial of 182 patients with non–ST-segment–elevation acute
coronary syndrome showing a similar reduction in the hsCRP
values with 14 days of once-daily anakinra treatment,26 but
no data on the incidence of HF were provided. In contrast with
the MRC-ILA Heart trial,26 however, treatment with anakinra
in this study appeared to have no effect on recurrent ischemic
events, whereas an unexpected, and unexplained, excess of
late recurrent ischemic events were seen in the MRC-ILA
Heart trial, raising the concern that 2-week treatment with
anakinra was associated with an unexpected untoward late
deleterious effect, possibly because of a rebound inﬂammatory mechanism. Reassuringly, no rebound, or excess, adverse
events were seen in the current study, nor in other studies of
anakinra used to treat patients with HF.10–12,25 Moreover, the

Anakinra (combined)

0
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180
270
360
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Recurrent Ischemic Events, %

Log-rank Test,
P = 0.046

HF Hospitalization or Death, %

30
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Although not powered to detect differences in clinical
outcomes, the prespeciﬁed analysis of HF outcomes showed a
signiﬁcantly lower incidence of HF hospitalizations and of new
or worsening HF with anakinra versus placebo. The results of
the VCUART3 are consistent with the ﬁndings of the prior pilot
feasibility VCUART and VCUART210,11 that enrolled a total 40
patients with STEMI and demonstrated a nominally lower
incidence of HF at 3 months (5% versus 30%; P=0.035) that
persisted at long-term follow-up.10–12 The results of the
VCUART3 are also in agreement with the analysis of 10 061
patients in the CANTOS clinical trial of canakinumab, an
interleukin-1b blocking antibody, in stable patients with prior
myocardial infarction, in whom canakinumab provided a
signiﬁcant reduction in hsCRP and a dose-dependent reduction in hospitalizations for HF.13,14

Log-rank Test,
P=0.55

25
20

Placebo

15
10

Anakinra (combined)

5
0

0

90
180
270
360
Days Since Randomization

Figure 3. Effects of anakinra on heart failure clinical events. Anakinra-treated patients had a signiﬁcantly lower in incidence of heart
failure related clinical events than placebo (Log-rank Mantel-Cox test). Left, a composite end point of new onset heart failure or death.
Middle, a composite end point of hospitalization for heart failure or death. Right, a composite of ischemic events (death, recurrent AMI, or
urgent revascularization).
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Study Limitations
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The major limitations of this phase 2 study are the small sample
size and the missing data. Despite these limitations, the
statistical signiﬁcance in the reduction in hsCRP levels is strong,
and it paired with a favorable safety proﬁle of the drug. The
preliminary signal for reduced incidence of new or worsening
HF, on the other hand, requires conﬁrmation and opens the way
to a new therapeutic strategy to be further tested in phase 3
clinical trials. Interleukin-1 blockade may represent the ﬁrst
targeted anti-inﬂammatory strategy treatment to prevent and
treat HF in patients with STEMI. Conﬁrmatory phase 2B/3
clinical trials are needed. A slight, not statistically signiﬁcant,
imbalance in the number of patients with diabetes mellitus is
noted between groups; nevertheless, the effects of anakinra on
AUC for hsCRP appeared to be independent of diabetes mellitus
status (data not shown).

Conclusions
Among patients with STEMI, interleukin-1 blockade with
anakinra signiﬁcantly reduces the systemic inﬂammatory
response compared with placebo, without any signiﬁcant
difference between standard or high-dose regimens. Prespeciﬁed analyses on clinical end points observed a reduced
incidence of HF and reduced HF hospitalizations, supporting
the potential clinical beneﬁt of interleukin-1 blockade in
patients with acute myocardial infarction.
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Table S1. Inclusion and Exclusion criteria.

Inclusion Criteria
(Must meet all 3 inclusion criteria)
1) Presentation to the hospital with acute STEMI defined as chest pain (or equivalent) with an onset within 12
hours and ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous leads that
is new or presumably new
2) Coronary angiography for potential intervention completed within 12 hours of symptom onset, and enrollment
in the study within 12 hours of angiography (max 24 hours from symptom onset)
3) Age > 21 years

Exclusion Criteria
(None of the exclusion criteria should be present)
1)
2)
3)
4)
5)
6)
7)
Downloaded from http://ahajournals.org by on June 5, 2020

Inability to give informed consent
Pregnancy or breastfeeding
Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association III-IV)
Preexisting severe left ventricular dysfunction (EF<20%)
Preexisting severe valvular heart disease
Active infections (acute or chronic)
Recent (<14 days) or active use of immunosuppressive drugs (including but not limited to high-dose
corticosteroids [>1_mg/kg of prednisone equivalent], TNF- blockers, cyclosporine) not including NSAIDs
or corticosteroids used for IV dye allergy only)
8) Chronic auto-immune or auto-inflammatory disease (including but not limited to rheumatoid arthritis,
systemic lupus erythematosus)
9) Known active malignancy of any type, or prior diagnosis in the past 10 years
10) Anticipated need for cardiac surgery
11) Active cancer (or prior diagnosis of cancer within the past 10 years, not considering in situ or localized
carcinomas treated with surgical resection alone)
12) Neutropenia (absolute neutrophil count<1,800/mm3 [or <1,000/mm3 in African-American patients])
13) Severe impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min/1.73 m2)
14) Allergy to rubber or latex
15) Allergy to products derived from Escherichia coli
STEMI=ST elevation myocardial infarction; ECG=electrocardiogram; AHA/ACC=Americxan Heart
Association/American College of Cardiology; EF=left-ventricular ejection fraction; TNF-=tumor necrosis
factor-alpha; NSAID=nonsteroidal anti-inflammatory drugs.

Table S2. Guideline-directed therapy at the beginning and at the end of the follow up.
At discharge

At end of follow up

Medication

Placebo
(N=35)

Anakinra
combined
(N=64)

P between
groups

Placebo
(N=33)

Anakinra
combined
(N=60)

P between
groups

Aspirin (%)

35 (100%)

64 (100%)

1.0

31 (94%)

57 (95%)

0.83

P2Y12 inhibitors (%)

35 (100%)

64 (100%)

1.0

31 (94%)

54 (90%)

0.52

Statins (%)

34 (97%)

64 (100%)

0.35

29 (88%)

57 (95%)

0.24

ACE-inhibitors or ARB (%)

30 (86%)

54 (84%)

0.86

26 (79%)

44 (73%)

0.62

2 (6%)

4 (6%)

1.0

4 (12%)

6 (10%)

0.74

27 (91%)

56 (88%)

0.74

31 (94%)

51 (85%)

0.32

Antiarrhythmics (%)

3 (9%)

2 (3%)

0.34

2 (6%)

1 (2%)

1.00

Long-acting Nitrates (%)

3 (9%)

2 (3%)

0.34

2 (6%)

2 (3%)

0.61

Diuretics (%)

5 (14%)

4 (6%)

0.27

5 (15%)

11 (18%)

0.78

Hydralazine (%)

4 (11%)

0

0.014

4 (12%)

0

0.014

Metformin (%)

3 (9%)

11 (17%)

0.37

5 (15%)

12 (20%)

0.78

10 (29%)

8 (12%)

0.06

9 (27%)

8 (13%)

0.16

Direct oral anticoagulants (%)

1 (3%)

4 (6%)

0.65

2 (6%)

2 (3%)

0.61

Vitamin K antagonist (%)

3 (9%)

2 (3%)

0.34

2 (6%)

0

0.12

0

0

1.0

1 (3%)

0

0.36

Mineralocorticoid receptor antagonists (%)
-adrenergic blockers (%)

Downloaded from http://ahajournals.org by on June 5, 2020

Insulin (%)

Digoxin (%)

Data are presented as number and percentage.
ACE=Angiotensin-converting enzyme; ARB=angiotensin receptor blocker.

Table S3. Clinical characteristics of subjects with paired echocardiogram.
Characteristics

Downloaded from http://ahajournals.org by on June 5, 2020

Age (years)
Female sex (%)
White / Black / Hispanic / Other
Previous diagnosis of CAD (%)
Previous diagnosis of HF (%)
Diabetes mellitus (%)
Hypertension (%)
Symptoms onset to PCI time
(min)
Symptoms to investigational drug
administration (min)
Fibrinolytic use prior to PCI (%)
Culprit vessel
LAD (%)
RCA (%)
Cx (%)
SVG (%)
TIMI flow grade 0/1 pre-PCI (%)
TIMI flow grade 3 post-PCI (%)
Coronary stent implantation (%)
Use of drug eluting stent (%)
Use of thrombectomy (%)

Anakinra once
daily (N=18)
56 [52 to 63]
5 (28%)
12 /6
3 (17%)
0
4 (22%)
10 (56%)

Anakinra twice
daily (N=21)
55 [44 to 60]
4 (19%)
14 / 7
4 (19%)
1 (4.8%)
6 (29%)
11 (52%)

Placebo
(N=24)
55 [50 to 60]
4 (17%)
17 / 7
9 (38%)
3 (13%)
9 (38%)
16 (68%)

205 [133 to 293]

124 [85 to 398]

182 [117 to 360]

0.621

518 [378 to 687]

380 [270 to 670]

485 [369 to 712]

0.363

0

4 (19%)

2 (8%)

0.162
0.544

7 (39%)
8 (44%)
2 (11%)
1 (6%)
18 (100%)
18 (100%)
18 (100%)
11 (61%)
2 (11%)

10 (48%)
7 (33%)
4 (19%)
0
17 (81%)
21 (100%)
21 (100%)
17 (81%)
4 (19%)

7 (29%)
13 (54%)
4 (17%)
0
18 (75%)
24 (100%)
24 (100%)
20 (83%)
4 (17%)

Data are presented as number and percentage or median and interquartile range for categorical or
continuous variables, respectively.
CAD=coronary artery disease; LCX=left circumflex artery; HF=heart failure; LAD=left anterior
descending artery; PCI=percutaneous coronary intervention; RCA=right coronary artery;
SVG=saphenous venous graft; TIMI=Thrombolysis In Myocardial Infarction

P value
0.481
0.662
0.942
0.220
0.242
0.555
0.592

0.163
1
1
0.204
0.788

Figure S1. Individual values of C-reactive protein area-under-the-curve values.
Anakinra once daily or twice daily significantly reduced the C-reactive protein area-under-the-curve
(CRP AUC) at 14 days (P<0.001 for all comparisons), without any significant differences between the
once daily and twice daily regimens.
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Figure S2. Effects of anakinra once daily and anakinra twice daily on heart failure events.
Kaplan-Meier survival curves for anakinra once daily, anakinra twice daily, and placebo are shown for the
composite endpoint of death or heart failure (P=0.14 between groups) and for death and hospitalization for
heart failure (P=0.038 between groups)(Log-rank test). No significant differences were found comparing
anakinra once daily with anakinra twice daily.
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Figure S3. Effects of anakinra on stroke volume and stroke work.
Anakinra led to a significant improvement in stroke volume (P=0.001 versus baseline and P=0.027 for
time_x_group interaction versus placebo [central panel]) and stroke work (P=0.001 versus baseline
and P=0.004 for time_x_group interaction versus placebo [right panel]).
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